Skip to main content

Immunogenicity and protective efficacy of intranasal delNS1(H5N1) influenza vaccine

Objective

The aim of the project is to characterize replication-deficient pandemic influenza vaccine candidates (H5N1) in clinical and preclinical studies. The replication-deficient vaccine is based on the deletion of the NS1 protein (DelNS1 vaccine).
First, several vaccine candidates will be screened for parameters including antigenic properties, receptor specificity, attenuation and immunogenicity in animal models. Studies on elucidation of mechanisms responsible for protection will comprise parameters of innate an d adaptive immunity.
Several standardized immunological techniques such as hemagglutination inhibition (HI) and ELISA will be used for evaluation of vaccine candidates. In addition, novel sensitive methods based on synthetic sialic receptor analogues will be developed for assessment of the antibody response against the hemagglutinin (HA) and neuraminidase (NA). Protective properties of the vaccine against homologous and heterologous influenza strains will be tested in ferret challenge experiments using dif ferent H5 strains. To close the gap between the ferret model and human studies we will use the macaque model to evaluate the immune response.
These pre-clinical studies will allow the selection of the most potent vaccine candidate, which will be produced according to cGMP guidelines on Vero cells. After toxicological evaluation of the vaccine, clinical phase I/II studies will be performed. If permitted by authorities, a human challenge study using attenuated H5 virus will be carried out. Alternatively, for proof of principle of the delNS technology, an H1-delNS1 vaccine will be produced and used in an H1 challenge study.

Call for proposal

FP6-2005-SSP-5-B-INFLUENZA
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
Address
Gersthofer Strasse 29-31
Vienna
Austria

Participants (5)

BIOTEST S.R.O.
Czechia
Address
Pod Zamken 279
Konarovice
SHEMYAKIN & OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY RUSSIAN ACADEMY OF SCIENCE
Russia
Address
Miklukho-maklaya 16/10
Moscow
RETROSCREEN VIROLOGY LTD.
United Kingdom
Address
327 Mile End Road
London
KLINIKUM DER JOHANN WOLFGANG GOETHE-UNIVERSITÄT
Germany
Address
Theodor Stern Kai 7
Frankfurt Am Main
MEDIZINISCHE UNIVERSITÄT WIEN
Austria
Address
Spitalgasse 23
Vienna